Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY Presented Positive GOBLET Pancreatic Cancer Data @ ESMO

<< Previous

Bullboard Posts

Next >>

Comment by Peladawnon Dec 02, 2023 5:06pm

149 Views

Post# 35765412

RE:RE:RE:ONCY Presented Positive GOBLET Pancreatic Cancer Data @ ESMO

Hey note.....thank you again for your posts.....these are the facts....period....no matter how people try to spin it.....Pela is soon likely to be approved, ....and that could possibly affect our current share priice

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading